このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Transgene 過去の業績

この会社の最新の決算報告書はまだ処理中です

過去基準チェック /06

Transgeneの収益は年間平均-37.8%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間11.8% 2.4%割合で増加しています。

主要情報

-37.8%

収益成長率

-35.7%

EPS成長率

Biotechs 業界の成長	30.8%
収益成長率	2.4%
株主資本利益率	-143.0%
ネット・マージン	-282.6%
次回の業績アップデート	07 Nov 2024

Recent updates

Is Transgene (EPA:TNG) Using Too Much Debt?

Jun 15

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23

収支内訳

Transgene の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ENXTPA:TNG 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	8	-22	7	0
30 Sep 23	8	-28	7	0
30 Jun 23	9	-33	7	0
31 Mar 23	10	-33	8	0
31 Dec 22	10	-33	8	0
30 Sep 22	14	-28	8	0
30 Jun 22	18	-23	8	0
31 Mar 22	18	-21	8	0
31 Dec 21	17	-20	7	0
30 Sep 21	13	-23	7	0
30 Jun 21	9	-27	6	0
31 Mar 21	9	-22	6	0
31 Dec 20	10	-17	7	0
30 Sep 20	12	-11	7	0
30 Jun 20	14	-6	7	0
31 Mar 20	14	-12	7	0
31 Dec 19	13	-19	7	0
30 Sep 19	11	-6	7	0
30 Jun 19	8	8	8	0
31 Mar 19	8	8	7	0
31 Dec 18	7	8	7	0
30 Sep 18	7	-10	6	4
30 Jun 18	7	-29	6	9
31 Mar 18	7	-31	6	15
31 Dec 17	7	-32	6	22
30 Sep 17	8	-32	6	22
30 Jun 17	9	-31	6	22
31 Mar 17	9	-28	6	20
31 Dec 16	10	-24	6	18
30 Sep 16	10	-26	6	19
30 Jun 16	9	-28	6	20
31 Mar 16	9	-33	6	22
31 Dec 15	10	-38	6	24
30 Sep 15	10	-40	6	25
30 Jun 15	10	-42	7	26
31 Mar 15	11	-41	7	26
31 Dec 14	11	-41	8	27
30 Sep 14	13	-41	7	28
30 Jun 14	15	-41	7	30
31 Mar 14	15	-42	7	32
31 Dec 13	16	-43	7	34
30 Sep 13	15	-44	7	34

質の高い収益: TNGは現在利益が出ていません。

利益率の向上: TNGは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: TNGは利益が出ておらず、過去 5 年間で損失は年間37.8%の割合で増加しています。

成長の加速: TNGの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: TNGは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。

株主資本利益率

高いROE: TNGは現在利益が出ていないため、自己資本利益率 ( -143.02% ) はマイナスです。

Transgene 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

Recent updates

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

Consensus revenue estimates fall by 45%

Is Transgene (EPA:TNG) Using Too Much Debt?

New major risk - Financial position

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

Price target decreased by 11% to €3.50

New major risk - Financial position

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Consensus revenue estimates fall by 15%

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released: EPS: €0 (vs €0.14 loss in 1H 2021)

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Consensus forecasts updated

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Consensus forecasts updated

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day high: €2.70

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.77

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

New 90-day high: €1.75

Transgene Appoints Hedi Ben Brahim as Chief Executive Officer, Effective January 1, 2021

First half 2020 earnings released: €0.03 loss per share

過去基準チェック /06